Dietrich John Pauls MBA Net Worth

The estimated Net Worth of Dietrich John Pauls is at least $988 Thousand dollars as of 23 June 2023. Mr Pauls owns over 12,787 units of DiaMedica Therapeutics stock worth over $300,429 and over the last 6 years he sold DMAC stock worth over $0. In addition, he makes $687,579 as Pres and CEO & Director at DiaMedica Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr MBA DMAC stock SEC Form 4 insiders trading

Mr has made over 4 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 12,787 units of DMAC stock worth $49,997 on 23 June 2023.

The largest trade he's ever made was buying 12,787 units of DiaMedica Therapeutics stock on 23 June 2023 worth over $49,997. On average, Mr trades about 2,379 units every 165 days since 2018. As of 23 June 2023 he still owns at least 68,591 units of DiaMedica Therapeutics stock.

You can see the complete history of Mr Pauls stock trades at the bottom of the page.

Mr. Dietrich John Pauls MBA biography

Dietrich John Pauls MBA is the Pres, CEO & Director at DiaMedica Therapeutics.

What is the salary of Mr MBA?

As the Pres and CEO & Director of DiaMedica Therapeutics, the total compensation of Mr MBA at DiaMedica Therapeutics is $687,579. There are no executives at DiaMedica Therapeutics getting paid more.

How old is Mr MBA?

Mr MBA is 50, he's been the Pres and CEO & Director of DiaMedica Therapeutics since . There are 5 older and no younger executives at DiaMedica Therapeutics. The oldest executive at DiaMedica Therapeutics Inc. is Dr. Harry W. Alcorn Jr., Pharm.D., 65, who is the Sr. VP of Clinical Operations.

What's Mr MBA's mailing address?

Dietrich's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.

Insiders trading at DiaMedica Therapeutics

Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg, and David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.

What does DiaMedica Therapeutics do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Complete history of Mr Pauls stock trades at DiaMedica Therapeutics

DiaMedica Therapeutics executives and stock owners

DiaMedica Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich John Pauls MBA,
  Pres, CEO & Director
• Rick Pauls,
  President, Chief Executive Officer, Director
• Dr. Harry W. Alcorn Jr., Pharm.D.,
  Sr. VP of Clinical Operations
• Scott B. Kellen C.A.,
  CFO & Company Sec.
• James Parsons,
  Director
• Michael Giuffre,
  Independent Director
• Jerry Xiao,
  Director
• Harry Alcorn,
  Director
• Paul Papi,
  Vice President - Business Development
• Sydney Gilman,
  Vice President - Regulatory Affairs
• Scott Kellen,
  Chief Financial Officer, Corporate Secretary
• Richard Pilnik,
  Independent Chairman of the Board
• Dr. Edward G. Calamai Ph.D.,
  Consulting Head of Manufacturing
• Tanya Lewis,
  Director
• David J. Wambeke,
  Chief Business Officer
• Jantrill Ab Stahlberg,
  
• Dietrich John Pauls,
  President and CEO
• Zhenyu Xiao,
  Director
• Todd A. Verdoorn,
  Chief Scientific Officer
• Koch Thomas Tom Enterprise ...,
  
• Koch Thomas Tom Enterprise ...,
  
• Charles Pauling Semba,
  Director
• Amy L. Burroughs,
  Director
• Kirsten L Gruis,
  Chief Medical Officer
• Dominic R Cundari,
  Chief Commercial Officer
• Julie Van Orsdel Daves,
  SVP Clinical Development Oper.
• Masuoka K. Lorianne,
  Chief Medical Officer
• Richard Kuntz,
  Director